FDA approves biosimilar competition for J&J's Remicade drug
The Food and Drug Administration granted marketing approval to Inflectra, a biosimilar product to Horsham-based Janssen Biotech’s multibillion-dollar Remicade drug.
Janssen Biotech, which formerly operated as Centocor, is a subsidiary of Johnson & Johnson (NYSE: JNJ).
Inflectra, the second biosimilar product approved by the FDA, will be co-marketed by Celletrion, a Korean drug company and Pfizer (NYSE:PFE)
The FDA action allows Inflectra to be marketed as a treatment for some, but not all, of…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Health | Health Management | Marketing | Pfizer | Remicade